# George Petrocheilos > George Petrocheilos is a Series A investor at HealthCor Catalio Acquisition Corp backing Biotechnology. See 10 investments, check sizes, portfolio. Updated… - Type: Angel Investor - Fund: [HealthCor Catalio Acquisition Corp](https://shizune.co/investors/profile/healthcor-catalio-acquisition-corp) - Total investments: 10 - Last investment: Mar 2024 - Lead investor: 90% - Last updated: Aug 2026 - LinkedIn: https://www.linkedin.com/in/georgepetrocheilos/ - X (Twitter): https://twitter.com/georgecpetro - Website: http://www.camdenpartners.com/petrocheilos/ George Petrocheilos is a Series A investor at HealthCor Catalio Acquisition Corp focused on Biotechnology and Life Science. George Petrocheilos is the President at HealthCor Catalio Acquisition. George Petrocheilos attended The Johns Hopkins University. ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Biotechnology | 8 | 80% | | Life Science | 5 | 50% | | Medical | 4 | 40% | | Therapeutics | 3 | 30% | | Health Care | 1 | 10% | 8 industries tracked in total. ### Stage | Stage | Investments | Share | | --- | --- | --- | | Series A | 5 | 50% | | Series B | 2 | 20% | | Series C | 1 | 10% | ### Country | Country | Investments | Share | | --- | --- | --- | | United States | 6 | 60% | | France | 1 | 10% | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | Clasp Therapeutics | Clasp Therapeutics offers to reach of immuno-oncology with novel precision medicines that enable the immune system to identify and specifically destroy hard-to-treat tumors bearing common driver mutations, regardless of tumor type. | $150M | Series A | Mar 20, 2024 | | | Haystack Oncology | Haystack Oncology, an oncology company, uses the most recent circulating tumor DNA detection technology to enhance the diagnosis of minimum residual disease and provide superior therapy decision-making information. | $56M | Series A | Nov 16, 2022 | | | Anagenex | Anagenex is a seed stage biotechnology company building a novel platform for drug discovery focusing on difficult targets. | $30M | Series A | Jun 08, 2022 | | | Pheast Therapeutics | Pheast Therapeutics is a cancer immunotherapy company focused on developing novel checkpoint therapies to harness the innate immune system in the fight against cancer. It was founded in 2020 and headquartered in Palo Alto, California. | $76M | Series A | Apr 26, 2022 | | | Octant Bio | Octant Bio is a developer of synthetic technology used to improve health and treat disease. Its technology uses synthetic biology, genome engineering, next-generation sequencing, and computational tools to simultaneously measure the activity of thousands of receptor pathways in human cells that enable scientists to apply machine learning methods toengineer small molecules that interact with multiple receptors and unlock a new potential to treat complex diseases. | $80M | Series B | Apr 21, 2022 | | | Octant Bio | Octant Bio is a developer of synthetic technology used to improve health and treat disease. Its technology uses synthetic biology, genome engineering, next-generation sequencing, and computational tools to simultaneously measure the activity of thousands of receptor pathways in human cells that enable scientists to apply machine learning methods toengineer small molecules that interact with multiple receptors and unlock a new potential to treat complex diseases. | $80M | Series B | Apr 21, 2022 | | | DNA Script | DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results. | $35M | Series C | Jan 04, 2022 | | | DNA Script | DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results. | $165M | Series C | Oct 26, 2021 | | | Sensei Biotherapeutics | Sensei Biotherapeutics is a clinical-stage biotechnology company specializing in the field of next-generation cancer immunotherapies. The company developing novel biologics therapies targeting key components of the immune system for the treatment of cancers of unmet need. They are also focused on the discovery, development, and delivery ofmedicines that alter the treatment landscape and contributing value to patients and society.Sensei Biotherapeutics using its proprietary drug discovery platform to study and understand the tumor microenvironment and identify a new class of cancer immunotherapies that act through new biology and differentiated mechanisms. It brings together scientific leaders in biology, immunology, and oncology along with a highly experienced management team and scientific advisors. The company's platform, ImmunoPhage enables the generation of immune-activating agents that fully engage activation of both the innate and adaptive immune systems. Sensei Biotherapeutics is headquartered in Gaithersburg, Maryland with an office in Boston, MA, USA. | $30M | Series B | Jan 11, 2021 | | | Spiral Therapeutics | Spiral Therapeutics is a clinical stage pharmaceutical company delivering novel therapies for hearing loss. Through the use proprietary therapeutics and drug delivery technologies, Spiral is building a pipeline of advanced therapies in a field with large unmet needs and no approved therapies. Spiral’s lead candidate, LPT99, reached the clinic inDecember 2018. Spiral was launched in early 2016 and is headquartered in Brisbane, CA. | $5.6M | Series A | Dec 12, 2018 | | 10 of 10 investments shown. ## Co-investors - [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 4 deals together - [Allen & Company](https://shizune.co/investors/profile/allen-and-company) — VC Fund, 2 deals together - [Andreessen Horowitz](https://shizune.co/investors/profile/andreessen-horowitz) — VC Fund, 2 deals together - [Bristol-Myers Squibb](https://shizune.co/investors/profile/bristol-myers-squibb) — VC Fund, 2 deals together - [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 2 deals together - [Coatue](https://shizune.co/investors/profile/coatue) — VC Fund, 2 deals together ## About HealthCor Catalio Acquisition Corp VC Fund 1 contacts available at HealthCor Catalio Acquisition Corp. | Name | Title | Profile | | --- | --- | --- | | George Petrocheilos | President | https://shizune.co/investors/profile/george-petrocheilos | ## Similar investors ### Similar stage - [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund - [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund - [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund ## FAQ ### What does George Petrocheilos invest in? George Petrocheilos invests primarily in Biotechnology, Life Science and Medical startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### When did George Petrocheilos last invest? The most recent investment recorded for George Petrocheilos closed in Mar 2024. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co